ダウンロード数: 2664

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
56_677.pdf1.17 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.author塚本, 泰司ja
dc.contributor.author白井, 尚ja
dc.contributor.author酒本, 貞昭ja
dc.contributor.author秋山, 昭人ja
dc.contributor.author武内, 宏之ja
dc.contributor.author矢島, 通孝ja
dc.contributor.author寺尾, 工ja
dc.contributor.author遠藤, 之洋ja
dc.contributor.alternativeTsukamoto, Taijien
dc.contributor.alternativeShirai, Takashien
dc.contributor.alternativeSakamoto, Sadaakien
dc.contributor.alternativeAkiyama, Akihitoen
dc.contributor.alternativeTakeuchi, Hiroyukien
dc.contributor.alternativeYajima, Michitakaen
dc.contributor.alternativeTerao, Takumien
dc.contributor.alternativeEndo, Yukihiroen
dc.date.accessioned2011-01-28T09:23:50Z-
dc.date.available2011-01-28T09:23:50Z-
dc.date.issued2010-12-
dc.identifier.issn0018-1994-
dc.identifier.urihttp://hdl.handle.net/2433/134660-
dc.description.abstractWe investigated the effects of dutasteride on voiding and storage symptoms by a post-hoc analysis from two randomized, placebo-controlled, parallel-group studies (Japanese phase II study and phase III study) which assessed the efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia (BPH). Men aged 50 years and older, with a prostate volume of 30 cc or greater, an International Prostate Symptom Score (IPSS) of 8 or higher and maximal urinary flow rate of 15 ml/sec or lower were randomized to placebo or dutasteride groups. The number of subjects for the placebo and dutasteride groups was respectively 72 and 72 in the phase II study, and 185 and 193 in the phase III study. Questions 1, 3, 5 and 6 of IPSS were related to voiding symptoms, and Questions 2, 4 and 7 were related to storage symptoms. Changes between pre- and post-treatments were evaluated. In the phase II study, dutasteride significantly improved voiding symptoms and numerically improved storage symptoms compared with the placebo at week 24. In the phase III study, dutasteride significantly improved voiding and storage symptoms compared with the placebo after 52 weeks. These consistent results suggest that dutasteride is effective for both voiding and storage symptoms in Japanese men with BPH.en
dc.format.mimetypeapplication/pdf-
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.rights許諾条件により本文は2012-01-01に公開ja
dc.subjectBenign prostatic hyperplasiaen
dc.subjectDutasterideen
dc.subjectStorage symptomen
dc.subjectJapaneseen
dc.subject.ndc494.9-
dc.title前立腺肥大症男性における排尿症状および蓄尿症状に対するデュタステリドの効果ja
dc.title.alternativeThe Effects of Dutasteride on Voiding and Storage Symptoms in Men with Benign Prostatic Hyperplasiaen
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume56-
dc.identifier.issue12-
dc.identifier.spage677-
dc.identifier.epage682-
dc.textversionpublisher-
dc.sortkey01-
dc.address札幌医科大学泌尿器科学講座ja
dc.address医療法人社団敬愛会みどりクリニックja
dc.address医療法人恵愛会中村病院泌尿器科ja
dc.address医療法人社団三昭会渋谷新南口クリニックja
dc.address医療法人社団新ゆり武内クリニックja
dc.addressやじま泌尿器科クリニックja
dc.addressグラクソ・スミスクライン開発本部ja
dc.addressグラクソ・スミスクライン開発本部ja
dc.startdate.bitstreamsavailable2012-01-01-
dc.address.alternativeThe Department of Urology, Sapporo Medical University School of Medicineen
dc.address.alternativeMidori Clinicen
dc.address.alternativeThe Department of Urology, Nakamura Hospitalen
dc.address.alternativeShibuya Shin-Minamiguchi Clinicen
dc.address.alternativeShin-Yuri Takeuchi Clinicen
dc.address.alternativeYajima Urology Clinicen
dc.address.alternativeDevelopment and Medical Affairs Division, GlaxoSmithKlineen
dc.address.alternativeDevelopment and Medical Affairs Division, GlaxoSmithKlineen
dc.identifier.pmid21273805-
dcterms.accessRightsopen access-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.56 No.12

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。